Matthias Blamont

Britain secures 60 million doses of Sanofi/GSK coronavirus vaccine

29 Jul 2020

LONDON/PARIS Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.

Sanofi lifts earnings view as Regeneron stake sale boosts second quarter

29 Jul 2020

PARIS Sanofi raised its 2020 earnings forecast on Wednesday after its second-quarter results were boosted by cost cuts and the sale of most of its 20.6% stake in U.S. company Regeneron, although revenue was hit by the coronavirus crisis.

Sanofi treibt Abspaltung von Firma für Arznei-Wirkstoffe voran

17 Jul 2020

- von Matthias Blamont und Gwénaëlle Barzic und Arno Schuetze

Sanofi forges ahead with active ingredients spin-off - sources

17 Jul 2020

PARIS/FRANKFURT Sanofi is starting preparations for a stock market listing of its active ingredients business as the French drugmaker pushes ahead with a strategy focusing on its more profitable businesses, sources told Reuters.

French drugmaker Sanofi to cut up to 1,680 jobs in Europe

26 Jun 2020

PARIS French drugmaker Sanofi, which employs more than 100,000 people worldwide, confirmed on Friday it will axe up to 1,680 jobs in Europe to cut costs and lift profits.

EXCLUSIVE-Sanofi planning to cut up to 1,680 jobs in Europe

26 Jun 2020

PARIS, June 26 Sanofi said on Friday it is planning to slash up to 1,680 jobs in Europe, confirming what two sources familiar with the matter had previously told Reuters.

Exclusive: Sanofi considers job cuts as CEO seeks to reduce costs - sources

25 Jun 2020

PARIS Sanofi is considering cutting hundreds of jobs and will discuss potential steps with staff representatives over the coming days, five sources said on Thursday, the latest move by the French drugmaker's chief executive Paul Hudson to cut costs. Management will meet staff representatives on Friday and Monday next week to outline a restructuring plan, five sources familiar with the matter told Reuters. They declined to be identified as the plan is still confidential.

Sanofi eyes approval of COVID-19 vaccine by first half of 2021

23 Jun 2020

PARIS French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated. | Video

World News